Aurora Cannabis Inc. (NASDAQ:ACB) is among the 11 Best Pot Stocks to Buy According to Hedge Funds.
On February 17, Canaccord initiated coverage of Aurora Cannabis Inc. (NASDAQ:ACB) with a Buy rating and C$10 price target. The analyst characterizes the company as the leading medical cannabis operator in Canada and a foremost participant in key international medical markets, including Germany, Poland, Australia, and the United Kingdom. According to the initiation note, Aurora’s strategic domestic pivot toward a medical-first model has enabled expansion into structurally higher-margin international markets, where gross margins are approximately 2.5 times higher on average than those generated in its Canadian medical business. The firm views this mix shift as a durable driver of profitability and earnings quality.
Aurora Cannabis Inc. (NASDAQ:ACB) reported Q3 fiscal 2026 results on February 4 and reaffirmed its medical-first strategic direction. Management guided fiscal 2026 global medical cannabis net revenue growth of 10%–15% to $269–$281 million. Medical revenue represented approximately 81% of total net revenue and roughly 95% of adjusted gross profit in Q3, underscoring the segment’s earnings leverage. The company forecast consolidated adjusted EBITDA of $52–$57 million, representing 5%–10% year-over-year growth, alongside sustained strong adjusted gross margins (62% consolidated and 69% for medical in Q3).
Plant propagation revenue is expected to follow typical seasonality, with 65%–75% generated in the first half of the calendar year. Management noted one-time Q4 cash costs associated with exiting select Canadian consumer markets but expects EBITDA improvement thereafter. Aurora also filed an at-the-market program for up to $100 million to fund accretive initiatives such as cultivation expansion and M&A. The quarter closed with $154 million in cash and no cannabis-related debt, reinforcing balance sheet flexibility.
Founded in 2006 and headquartered in Alberta, Canada, Aurora Cannabis Inc. (NASDAQ:ACB) cultivates, produces, and distributes medical and recreational cannabis products under federal licensing frameworks.
While we acknowledge the potential of ACB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ACB and that has a 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 12 Best Retail Stocks to Buy According to Analysts and 13 Best Internet of Things (IoT) Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
